The prospects of hepatic drug delivery and gene therapy

J. Wu, G. Y. Wu, Mark A Zern

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been designed and further modified for selective targeting of therapeutics to the liver. The targeting properties and strategies of commonly used agents, such as liposomes, microspheres and recombinant chylomicrons, are discussed. Viral and non-viral vectors, such as cationic liposomes, reconstituted chylomicron remnants, adenoviruses, adeno-associated viruses, retroviruses, and SV-40, are currently being evaluated for the delivery of DNA to the liver. New developments in improving the targeting efficiency of the available vectors while avoiding their disadvantages have made their use in clinical trials of various genetic disorders possible. For viral hepatitis, antisense and ribozyme techniques are being employed with selective targeting approaches. A commonly employed current strategy for targeting hepatocellular carcinoma cells is to make the tumour cells convert non-toxic 'prodrugs' to toxic metabolites in situ, achieving a high concentration of the toxic product in the local milieu, while avoiding systemic toxicity. Although gene therapy itself is in its infancy, some encouraging results have been developed in studies of familial hypercholesterolaemia, haemophilia, α1-antitrypsin deficiency and Crigler-Najjar syndrome. The potential strengths as well as the problems with these studies are discussed.

Original languageEnglish (US)
Pages (from-to)1795-1817
Number of pages23
JournalExpert Opinion on Investigational Drugs
Volume7
Issue number11
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Genetic Therapy
Drug Therapy
Poisons
Liver
Liposomes
Crigler-Najjar Syndrome
Chylomicron Remnants
Chylomicrons
Dependovirus
Catalytic RNA
Inborn Genetic Diseases
Hyperlipoproteinemia Type II
Prodrugs
Hemophilia A
Therapeutic Uses
Retroviridae
Microspheres
Adenoviridae
Hepatitis
Hepatocellular Carcinoma

Keywords

  • α1-antitrypsin deficiency
  • Adeno-associated virus
  • Adenovirus
  • Antisense
  • Asialofetuin
  • Asialoglycoprotein receptor
  • Chylomicron remnant
  • Crigler-Najjar syndrome
  • Familial hypercholesterolaemia
  • Gene therapy
  • Haemophilia B
  • Hepatitis B virus
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Hepatocyte
  • Kupffer cell
  • Liposome
  • Microsphere
  • Retrovirus
  • Ribozyme
  • Sinusiodal endothelial cell
  • SV40
  • Targeting therapy
  • Viral hepatitis

ASJC Scopus subject areas

  • Pharmacology

Cite this

The prospects of hepatic drug delivery and gene therapy. / Wu, J.; Wu, G. Y.; Zern, Mark A.

In: Expert Opinion on Investigational Drugs, Vol. 7, No. 11, 1998, p. 1795-1817.

Research output: Contribution to journalArticle

Wu, J. ; Wu, G. Y. ; Zern, Mark A. / The prospects of hepatic drug delivery and gene therapy. In: Expert Opinion on Investigational Drugs. 1998 ; Vol. 7, No. 11. pp. 1795-1817.
@article{3170e43bb8ed4c8d854fc29cd0424de0,
title = "The prospects of hepatic drug delivery and gene therapy",
abstract = "Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been designed and further modified for selective targeting of therapeutics to the liver. The targeting properties and strategies of commonly used agents, such as liposomes, microspheres and recombinant chylomicrons, are discussed. Viral and non-viral vectors, such as cationic liposomes, reconstituted chylomicron remnants, adenoviruses, adeno-associated viruses, retroviruses, and SV-40, are currently being evaluated for the delivery of DNA to the liver. New developments in improving the targeting efficiency of the available vectors while avoiding their disadvantages have made their use in clinical trials of various genetic disorders possible. For viral hepatitis, antisense and ribozyme techniques are being employed with selective targeting approaches. A commonly employed current strategy for targeting hepatocellular carcinoma cells is to make the tumour cells convert non-toxic 'prodrugs' to toxic metabolites in situ, achieving a high concentration of the toxic product in the local milieu, while avoiding systemic toxicity. Although gene therapy itself is in its infancy, some encouraging results have been developed in studies of familial hypercholesterolaemia, haemophilia, α1-antitrypsin deficiency and Crigler-Najjar syndrome. The potential strengths as well as the problems with these studies are discussed.",
keywords = "α1-antitrypsin deficiency, Adeno-associated virus, Adenovirus, Antisense, Asialofetuin, Asialoglycoprotein receptor, Chylomicron remnant, Crigler-Najjar syndrome, Familial hypercholesterolaemia, Gene therapy, Haemophilia B, Hepatitis B virus, Hepatitis C virus, Hepatocellular carcinoma, Hepatocyte, Kupffer cell, Liposome, Microsphere, Retrovirus, Ribozyme, Sinusiodal endothelial cell, SV40, Targeting therapy, Viral hepatitis",
author = "J. Wu and Wu, {G. Y.} and Zern, {Mark A}",
year = "1998",
doi = "10.1517/13543784.7.11.1795",
language = "English (US)",
volume = "7",
pages = "1795--1817",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - The prospects of hepatic drug delivery and gene therapy

AU - Wu, J.

AU - Wu, G. Y.

AU - Zern, Mark A

PY - 1998

Y1 - 1998

N2 - Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been designed and further modified for selective targeting of therapeutics to the liver. The targeting properties and strategies of commonly used agents, such as liposomes, microspheres and recombinant chylomicrons, are discussed. Viral and non-viral vectors, such as cationic liposomes, reconstituted chylomicron remnants, adenoviruses, adeno-associated viruses, retroviruses, and SV-40, are currently being evaluated for the delivery of DNA to the liver. New developments in improving the targeting efficiency of the available vectors while avoiding their disadvantages have made their use in clinical trials of various genetic disorders possible. For viral hepatitis, antisense and ribozyme techniques are being employed with selective targeting approaches. A commonly employed current strategy for targeting hepatocellular carcinoma cells is to make the tumour cells convert non-toxic 'prodrugs' to toxic metabolites in situ, achieving a high concentration of the toxic product in the local milieu, while avoiding systemic toxicity. Although gene therapy itself is in its infancy, some encouraging results have been developed in studies of familial hypercholesterolaemia, haemophilia, α1-antitrypsin deficiency and Crigler-Najjar syndrome. The potential strengths as well as the problems with these studies are discussed.

AB - Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been designed and further modified for selective targeting of therapeutics to the liver. The targeting properties and strategies of commonly used agents, such as liposomes, microspheres and recombinant chylomicrons, are discussed. Viral and non-viral vectors, such as cationic liposomes, reconstituted chylomicron remnants, adenoviruses, adeno-associated viruses, retroviruses, and SV-40, are currently being evaluated for the delivery of DNA to the liver. New developments in improving the targeting efficiency of the available vectors while avoiding their disadvantages have made their use in clinical trials of various genetic disorders possible. For viral hepatitis, antisense and ribozyme techniques are being employed with selective targeting approaches. A commonly employed current strategy for targeting hepatocellular carcinoma cells is to make the tumour cells convert non-toxic 'prodrugs' to toxic metabolites in situ, achieving a high concentration of the toxic product in the local milieu, while avoiding systemic toxicity. Although gene therapy itself is in its infancy, some encouraging results have been developed in studies of familial hypercholesterolaemia, haemophilia, α1-antitrypsin deficiency and Crigler-Najjar syndrome. The potential strengths as well as the problems with these studies are discussed.

KW - α1-antitrypsin deficiency

KW - Adeno-associated virus

KW - Adenovirus

KW - Antisense

KW - Asialofetuin

KW - Asialoglycoprotein receptor

KW - Chylomicron remnant

KW - Crigler-Najjar syndrome

KW - Familial hypercholesterolaemia

KW - Gene therapy

KW - Haemophilia B

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Hepatocyte

KW - Kupffer cell

KW - Liposome

KW - Microsphere

KW - Retrovirus

KW - Ribozyme

KW - Sinusiodal endothelial cell

KW - SV40

KW - Targeting therapy

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=0031759780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031759780&partnerID=8YFLogxK

U2 - 10.1517/13543784.7.11.1795

DO - 10.1517/13543784.7.11.1795

M3 - Article

C2 - 15991930

AN - SCOPUS:0031759780

VL - 7

SP - 1795

EP - 1817

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 11

ER -